Model No.: H010.S01001
Test Method: HPLC
Latin Name: Lycopodium Serratum Thunb
Active Ingredient: Huperzine A
Appearance: Light Yellow Powder To White Powder
Specfication: 1%
CAS No.: 102518-79-6
Source: Lycopodium Serratum Thunb Whole Herb
Packaging: Drum, Plastic Container, Vacuum Packed, OEM Services Provide
Productivity: 30 Ton per Month
Brand: OHI
Transportation: Ocean,Land,Air
Place of Origin: China
Supply Ability: 30 Ton per Month
Certificate: HACCP,ISO, Halal, Kosher
OHI's Huperzine A is extract from natural Huperzia Serrata (Lycopodium serratum Thunb), Lycopodium serratum is a genus of Lycophyte plants, sometimes known as the firmosses or fir clubmosses. This genus was originally included in the related genus Lycopodium, from which it differs in having undifferentiated sporangial leaves, and the sporangia not formed into apical cones. The common name firmoss, used for some of the north temperate species, refers to their superficial resemblance to branches of fir (Abies), a conifer. In Australia, the epiphytic species are commonly known as tassel ferns.
Huperzine A is a naturally occurring sesquiterpene alkaloid compound found in the firmoss (Huperzia serrata) and in varying quantities in other Huperzia species, including H. elmeri, H. carinat, and H. aqualupian.
Huperzine A has been found, through multiple studies, to be effective as a medicine for helping people with neurological conditions such as Alzheimer's disease, but the meta-analysis of those studies concluded that they were poor quality and the findings should be interpreted with caution.Huperzine A is extracted from Huperzia serrata. It is a reversible acetylcholinesterase inhibitor and NMDA receptor antagonist that crosses the blood-brain barrier. The structure of the complex of huperzine A with acetylcholinesterase has been determined by X-ray crystallography (PDB code: 1VOT; see the 3D structure).
For some years, huperzine A has been investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer's disease. A 2013 meta-analysis found that huperzine A may be efficacious in improving cognitive function, global clinical status, and activities of daily living for individuals with Alzheimer`s disease. However, due to the poor size and quality of the clinical trials reviewed, huperzine A should not be recommended as a treatment for Alzheimer`s disease until further high quality studies confirm its beneficial effects.
Huperzine A is also marketed as a dietary supplement with claims made for its ability to improve memory and mental function. Huperzine A may also have a possible role in the treatment of myasthenia gravis.
Product Categories : Active Pharmaceutical Ingredient (API)